Wednesday, July 23, 2014
Inquirer Daily News

Drug-price push back, even with cancer medicine

More and more drug companies can't assume that any drug they put forth will automatically be reimbursed by insurance companies at whatever price tag the drug company slaps on the product.

Drug-price push back, even with cancer medicine

In this Aug. 5, 2010, file photo, a pharmacy tech poses for a picture with hydrocodone bitartrate and acetaminophen tablets, the generic version of Vicodin, at Oklahoma Hospital Discount Pharmacy in Edmond, Okla. Sales of the nation’s two most popular prescription painkillers have exploded in new parts of the country, an Associated Press analysis shows, worrying experts who say the push to relieve patients’ suffering is spawning an addiction epidemic. From New York’s Staten Island to Santa Fe, N.M., Drug Enforcement Administration figures show dramatic rises between 2000 and 2010 in the distribution of oxycodone, the key ingredient in OxyContin, Percocet and Percodan. (AP Photo/Sue Ogrocki, File)
In this Aug. 5, 2010, file photo, a pharmacy tech poses for a picture with hydrocodone bitartrate and acetaminophen tablets, the generic version of Vicodin, at Oklahoma Hospital Discount Pharmacy in Edmond, Okla. Sales of the nation’s two most popular prescription painkillers have exploded in new parts of the country, an Associated Press analysis shows, worrying experts who say the push to relieve patients’ suffering is spawning an addiction epidemic. From New York’s Staten Island to Santa Fe, N.M., Drug Enforcement Administration figures show dramatic rises between 2000 and 2010 in the distribution of oxycodone, the key ingredient in OxyContin, Percocet and Percodan. (AP Photo/Sue Ogrocki, File)

More and more drug companies can't assume that any drug they put forth will automatically be reimbursed by insurance companies at whatever price tag the drug company slaps on the product.

A Reuters story, whose link is here, reported on a recent example and is based in part on a PricewaterhouseCoopers survey of U.S. health insurers. PwC's survey indicated that four-fifths of insurers polled now require evidence of cost savings or a clear clinical benefit to include new products on their lists of covered drugs.

"In cases where there are co-pays, they really do effect the consumer," said Mark Mynhier, partner, healthcare industries advisory at PricewaterhouseCoopers, according to Reuters. "Patients are saying 'I can't afford to pay 10 or 20 percent of a $100,000 therapy.' "

The story noted that doctors at New York's Memorial Sloan-Kettering Cancer Center opted for a lesser-priced cancer drug. Reuters said they decided in November not to use Zaltrap, a new $11,000 a month colon cancer drug, because it has a "modest" impact on survival, works no better than Avastin, a similar but cheaper competitor, and has worse side effects. The hospital said Sanofi aventis, which makes the drug, offered a discount on the wholesale price, but that was not enough to make the hospital's list of available drugs.

"In order to warrant the price, you are going to have to have better overall survival," said Rhonda Greenapple, chief executive at Reimbursement Intelligence, a consulting firm specializing in medical reimbursement, according to Reuters.

David Sell
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com.

David Sell
Business Videos:
Also on Philly.com:
Stay Connected